Alkem Laboratories Ltd (ALKEM)
₹5,113.50
Mkt cap
₹61,140 Cr
P/E ratio
26.90
P/B
4.42
Div yield
1.04%
ROE
18.90%
ROCE
21.20%
EPS (TTM)
₹190.09
Book value
₹1,156
52W range
4,811–5,934
Sector
Healthcare
Price history
Previous close
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
NSE ALKEMBSE 539523
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−13.82% from high₹5,114
₹4,811+6.29% from low₹5,934
Current
₹5,113.50
Prev close
₹5,079.00
Day
+0.68%
Price performance
1D
+0.68%
1W
+3.37%
1M
−2.60%
3M
−12.09%
6M
−4.31%
1Y
−7.60%
YTD
−8.57%
Financials
Revenue, profit & margin
P/E ratio
26.9×
ALKEM is 21% below the sector median of 34.0×
ALKEM26.9×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,968 | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 | |
| Expenses | 2,579 | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 | |
| Operating Profit | 389 | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 | |
| OPM % | 13% | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% | |
| Other Income | 66 | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 | |
| Interest | 30 | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 | |
| Depreciation | 72 | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 | |
| Profit before tax | 353 | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 | |
| Tax % | 18% | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% | |
| Net Profit | 288 | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 | |
| EPS in Rs | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 | 43.49 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.53% · closed higher next day 17 of last 42
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25† | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 9 Feb '24◦ | 29 May '24◦ | 9 Aug '24◦ | 13 Nov '24◦ | 7 Feb '25◦ | 29 May '25 | 12 Aug '25 | 13 Nov '25 | 13 Feb '26 | 28 May '26◦ | 14 Aug '26◦ |
| Earnings day | +5.10% | −3.35% | −6.00% | −1.41% | −0.83% | −6.80% | −3.70% | +6.29% | −0.73% | −7.97% | +0.85% | +0.11% |
| +1 day | +6.34% | −0.65% | −8.59% | −1.51% | −1.01% | −8.69% | −3.74% | +11.23% | −0.78% | −6.64% | −2.51% | +1.99% |
| +5 days | +8.29% | +2.70% | −7.75% | −1.10% | −1.67% | −6.93% | −8.16% | +11.32% | −1.17% | −8.15% | −3.67% | −0.34% |
| +15 days | +15.41% | −3.81% | −2.53% | +5.38% | −1.55% | −10.42% | −9.84% | +9.43% | −1.88% | −6.99% | −1.43% | −2.34% |
| +30 days | +22.03% | −6.08% | −1.21% | +4.31% | +1.13% | −2.88% | −9.21% | +13.70% | −4.03% | −10.66% | +2.12% | −2.20% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202649.70%Promoter
Promoters49.70%
FIIs10.32%0.10
DIIs22.83%0.19
Public17.14%0.11
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Alkem Lab | ₹5,113.50 | 26.90 | 61,140 | 1.04% | 521 | −20.47% | 3,740 | +10.95% | 21.24% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts90
TranscriptAug 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026PPTFeb 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025PPTMar 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024PPTSep 2024TranscriptAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Oct - US FDA inspected Mandva API facility from 26–30 October 2026; concluded with no Form 483 observations.Announcement Under Regulation 30 (LODR)- Intimation Regarding Initiation Of Forensic Audit 21 Oct - On 21 Oct 2026, Alkem approved a forensic audit by Grant Thornton Bharat over alleged fund misappropriation.Announcement under Regulation 30 (LODR)-Change in Management 12 Oct - Alkem Laboratories appointed Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as senior management effective 12 October 2026.Announcement under Regulation 30 (LODR)-Cessation 24 Sep - Nitin Agrawal resigned as CFO on 30 July 2026; cessation effective 30 September 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep - Alkem Laboratories to meet HDFC Mutual Fund in Mumbai on 7 October 2026.